Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Aurinia Pharmaceuticals' Stock Jumped Today

By Cory Renauer – Updated Apr 20, 2019 at 5:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It looks like an important patent that could protect its lead candidate is a done deal.

What happened

Shares of Aurinia Pharmaceuticals (AUPH 0.94%), a clinical-stage biopharmaceutical company, are on the move after the U.S. Patent and Trademark Office (USPTO) issued an important notice. Investors looking forward to long-term market exclusivity pushed the biotech stock 14.9% higher as of 3:47 p.m. EST on Monday.

So what 

Doctors have been using ciclosporin to treat autoimmune disorders since the 1980s, and Aurinia's voclosporin is a slightly modified version of the old standby that isn't much younger. Since most composition-of-matter patents last just 20 years, Aurinia had to find another way to protect voclosporin's market exclusivity.

Happy guy wearing a vest and tie.

Image source: Getty Images.

The stock jumped today because it looks like the USPTO will soon issue a patent for Aurinia's only new drug candidate that protects the dosing protocol used in the pivotal Aurora study with lupus nephritis. Dosage protocols are a popular tool for extending the life of decades-old drugs, which means Aurinia probably won't have to worry about generic competition until December 2037 at the earliest.

Check out the latest Aurinia earnings call transcript.

Now what

Aurinia finished enrolling lupus nephritis patients in the Aurora study last September, and top-line results should be ready in the fourth quarter. If Aurora repeats results we saw in a smaller study, a new drug application for voclosporin as a lupus treatment could be ready to submit in the first half of 2020.

There are enough advanced-stage lupus patients in need of a new treatment option to make voclosporin a blockbuster drug, and an expansion to treat dry eye syndrome with an ophthalmic solution of the drug could make Aurinia a top stock in the years ahead. In a head-to-head trial with a standard treatment for dry eye, voclosporin wiped the floor with its potential competitor, Restasis.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurinia Pharmaceuticals Inc. Stock Quote
Aurinia Pharmaceuticals Inc.
AUPH
$7.52 (0.94%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.